Sight Sciences Inc - SIC # 3841 - SURGICAL AND MEDICAL INSTRUMENTS AND APPARATUS

Ticker Exchange SIC # Website Latest Ticker
SGHT Nasdaq 3841 https://www.sightsciences.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Sight Sciences Inc

Sight Sciences to Report First Quarter Financial Results on May 2, 2024 - Apr 18th, 2024 8:05 pm
Sight Sciences Announces the Publication of Large-Scale, Real-World MIGS Study Demonstrating the Comprehensive Aqueous Outflow Restorative Procedure with OMNI® Surgical System Technology is Effective at Lowering Both IOP and IOP Reducing Medications at 2 Years in Patients with Glaucoma - Apr 10th, 2024 8:05 pm
Sight Sciences Announces the Results of the Three-Year Prospective GEMINI Trial and the Cross-Over Phase of the SAHARA RCT at the 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting - Apr 2nd, 2024 8:05 pm
Sight Sciences to Present at the Upcoming 23rd Annual Needham Healthcare Conference - Mar 26th, 2024 8:05 pm
Sight Sciences, Inc. (NASDAQ:SGHT) Q4 2023 Earnings Call Transcript - Mar 8th, 2024 7:53 pm
Q4 2023 Sight Sciences Inc Earnings Call - Mar 8th, 2024 2:16 pm
Sight Sciences Inc (SGHT) Navigates Challenges to Maintain Revenue Growth and Reduce Expenses - Mar 8th, 2024 3:35 am
Sight Sciences, Inc. (SGHT) Reports Q4 Loss, Tops Revenue Estimates - Mar 7th, 2024 10:50 pm
Sight Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Initiates Full Year 2024 Financial Guidance - Mar 7th, 2024 9:05 pm
Sight Sciences to Report Fourth Quarter and Full Year 2023 Financial Results on March 7, 2024 - Feb 22nd, 2024 9:05 pm
Sight Sciences (SGHT) to Expand in Europe With New Launch - Feb 21st, 2024 3:25 pm
Sight Sciences Announces European Launch of the Ergo-Series of the OMNI® Surgical System at the ESCRS Winter Meeting - Feb 14th, 2024 9:05 pm
Sight Sciences Announces the Closing of up to $65 Million Senior Secured Credit Facility with Hercules Capital - Jan 23rd, 2024 9:05 pm
Sight Sciences Announces Preliminary, Unaudited Fourth Quarter and Full Year 2023 Financial Highlights - Jan 8th, 2024 9:05 pm
Sight Sciences Announces Withdrawal of Final LCDs on Micro-Invasive Glaucoma Surgery from Five Medicare Administrative Contractors - Dec 28th, 2023 2:15 pm
Sight Sciences Announces the Publication of Successful Results of the SAHARA Randomized Controlled Clinical Trial Comparing TearCare® to Restasis® for the Treatment of Dry Eye Disease - Dec 18th, 2023 9:05 pm
Sight Sciences Announces the Acceptance for Publication of GEMINI 2, a Three Year, Prospective, Multicenter Trial Demonstrating Sustained, Significant IOP and Medication Reductions Enabled with the OMNI® Surgical System Technology - Dec 8th, 2023 1:05 pm
Independent Chairman of Sight Sciences Picks Up 14% More Stock - Nov 24th, 2023 10:18 am
The Sight Sciences, Inc. (NASDAQ:SGHT) Analysts Have Been Trimming Their Sales Forecasts - Nov 19th, 2023 12:13 pm
5 Risky Stocks to Buy Immediately, According to AI - Nov 13th, 2023 8:40 pm